EDITAS MEDICINE, INC. Increase Decrease In Operating Lease Liability
EDITAS MEDICINE, INC. (EDIT) reported Increase Decrease In Operating Lease Liability of -$2.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-05
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$1.64M.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$805.00K.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.55M.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.48M.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for fiscal 2025 was -$12.08M.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for fiscal 2024 was -$1.50M.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for fiscal 2023 was -$7.41M, a 142.18% decline from fiscal 2022.
- EDITAS MEDICINE, INC. increase decrease in operating lease liability for fiscal 2022 was $17.57M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.44M 10-Q · filed 2026-08-05 | -$3.99M derived: sum of 3 quarters · filed 2026-08-05 | -$5.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$805.00K 10-Q · filed 2026-05-05 | -$2.35M derived: sum of 2 quarters · filed 2026-05-05 | -$3.84M derived: sum of 3 quarters · filed 2026-05-05 | -$8.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$3.03M derived: sum of 2 quarters · filed 2026-03-09 | -$8.18M derived: sum of 3 quarters · filed 2026-08-05 | -$12.08M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$6.63M derived: sum of 2 quarters · filed 2026-08-05 | -$10.53M 10-Q · filed 2025-11-10 | -$13.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$5.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$9.05M 10-Q · filed 2026-08-05 | -$12.50M derived: sum of 3 quarters · filed 2026-08-05 | -$12.71M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$3.90M 10-Q · filed 2026-05-05 | -$7.36M derived: sum of 2 quarters · filed 2026-05-05 | -$7.57M derived: sum of 3 quarters · filed 2026-05-05 | -$3.01M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$3.67M derived: sum of 2 quarters · filed 2026-03-09 | $892.00K derived: sum of 3 quarters · filed 2026-03-09 | -$1.50M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.35M derived: sum of 2 quarters · filed 2025-11-10 | $1.95M 10-Q · filed 2025-11-10 | $3.88M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.16M 10-Q · filed 2025-08-12 | $4.09M derived: sum of 3 quarters · filed 2025-08-12 | $1.51M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$2.40M 10-Q · filed 2025-05-12 | -$471.00K derived: sum of 2 quarters · filed 2025-05-12 | -$3.05M derived: sum of 3 quarters · filed 2025-05-12 | -$3.00M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$650.00K derived: sum of 2 quarters · filed 2025-03-05 | -$602.00K derived: sum of 3 quarters · filed 2025-03-05 | -$7.41M 10-K · filed 2025-03-05 |
| 2023-09-30 | -$2.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$2.53M derived: sum of 2 quarters · filed 2024-11-04 | -$9.34M 10-Q · filed 2024-11-04 | $13.31M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$6.76M 10-Q · filed 2024-08-07 | $15.89M derived: sum of 3 quarters · filed 2025-03-05 | $16.93M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | -$6.81M 10-Q · filed 2024-05-08 | $15.84M derived: sum of 2 quarters · filed 2025-03-05 | $16.88M derived: sum of 3 quarters · filed 2025-03-05 | $13.97M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $22.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $23.69M derived: sum of 2 quarters · filed 2025-03-05 | $20.78M derived: sum of 3 quarters · filed 2025-03-05 | $17.57M 10-K · filed 2025-03-05 |
| 2022-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$1.86M derived: sum of 2 quarters · filed 2023-11-03 | -$5.08M 10-Q · filed 2023-11-03 | -$8.38M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$6.12M 10-Q · filed 2023-08-02 | -$9.42M derived: sum of 3 quarters · filed 2024-02-28 | -$10.98M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | -$3.21M 10-Q · filed 2023-05-05 | -$6.51M derived: sum of 2 quarters · filed 2024-02-28 | -$8.08M derived: sum of 3 quarters · filed 2024-02-28 | -$16.46M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$4.86M derived: sum of 2 quarters · filed 2024-02-28 | -$13.24M derived: sum of 3 quarters · filed 2024-02-28 | -$10.49M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$9.95M derived: sum of 2 quarters · filed 2022-11-02 | -$7.20M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | -$8.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$5.63M 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $2.75M 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | -$2.95M 10-K · filed 2023-02-22 | |||
| 2019-12-31 | $9.32M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |